Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes

NCT00622752 | Completed Phase 2

• 2 other identifiers: EVT 302/3011EUDRACT No.: 2007-006236-63
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

This randomised, placebo-controlled study is designed to explore the effects of EVT 302 both with and without concomitant nicotine replacement therapy (NRT) on craving and withdrawal in smokers after short term deprivation of cigarettes.

Conditions

Smoking Cessation

Keywords

Smoking cessation; Craving; Smokers

Outcome Measures

Primary Outcomes (1)

• Reduction in Craving and withdrawal

  Within 12 hours of the last cigarette

Secondary Outcomes (5)

• CogState Cognitive test Battery

  12 hours post last cigarette

• Breath carbon monoxide levels

  12 hours post last cigarette

• Salivary cotinine levels

  12 hours post last cigarette

• Clinical safety lab tests

  Up to 7 days post dose

• Assessment of adverse events

  Up to 7 days post dose

Study Arms (4)

1

EXPERIMENTAL

EVT 302, 10 mg

Drug: EVT 302, 10 mg

2

EXPERIMENTAL

EVT 302, 10 mg + NRT patch, 21 mg

Drug: EVT 302, 10 mg; Drug: Nicotine replacement therapy (NRT)

3

EXPERIMENTAL

NRT patch, 21 mg

Drug: Nicotine replacement therapy (NRT)

4

PLACEBO COMPARATOR

Placebo to match EVT 302 and placebo patch to match NRT patch

Drug: placebo; Device: NRT placebo

Interventions

EVT 302, 10 mg DRUG

2 X EVT 302, 5 mg tablets

1; 2

placebo DRUG

2 X placebo tablets to match EVT 302 5 mg

4

Nicotine replacement therapy (NRT) DRUG

NRT patch containing 21 mg of nicotine

2; 3

NRT placebo DEVICE

Medically inert plaster cut to match the NRT plaster

4

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male subjects between 18 and 55 years of age, inclusive
• BMI between 18 and 30, minimum weight of 50 kg
• Negative urine drug \& alcohol screen
• Able to comply with tyramine-restricted diet
• Smoking of ≥17 and ≤34 cigarettes per day for the past year and have not tried to quit smoking in the 3 months prior to screening
• Subjects are willing and able to quit for about 12 hours in each of three subsequent study periods
• Previous experience of craving following smoking cessation
• Breath CO between 15 ppm and 20 ppm and cotinine in saliva and plasma at least 250 ng/mL at screening
• Liver function test results not above 1.5 times the upper normal limit (UNL) at screening visit and at re-assessment during the study.

You may not qualify if:

• Participation in another clinical study within 60 days of screening
• Evidence of active significant psychiatric or neurological disease or dependency other than cigarettes
• Are known to have or are a carrier of the hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, has a positive result to the human immunodeficiency virus-1 and/or 2 (HIV-1 and/or HIV-2) antibodies
• Known hypersensitivity to MAO inhibitors or any substance that is contained in the study formulations
• Known allergy to plasters or NRT patches
• Previous participation in another study with EVT 302
• Currently receiving treatment for smoking cessation
• Current use of tobacco products other than cigarettes
• Require treatment with any medication
• Subject with a clinically relevant abnormal 12-lead ECG recording or QTcB/F \>430 ms
• Use of a prescription medicine within 14 days or 5 half-lives, whichever is the longer, of the start of dosing, or use of an over-the-counter medication during the 7 days before the study, including herbal remedies, but excluding paracetamol and vitamin supplements (provided intake does not exceed the daily recommended allowance)
• Subjects must not be planning to father a child or donate sperm, during the study and 3 months after the end of the study. Acceptable methods of contraception comprise barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least 2 month)
• Daily consumption of more than 5 cups of tea or coffee, or more than 1.0 litre of xanthine-containing drinks
• Recent myocardial infarction, unstable or worsening angina pectoris, prince metal angina, severe arrhythmias, recent stroke.
• Creatinine clearance (CLR) calculated according to the formula by Modification of Diet in Renal Disease (MDRD) of \<80 mL/min

Sponsors & Collaborators

• Evotec Neurosciences GmbH: lead

Study Sites (1)

PAREXEL International GmbH, Clinical Pharmacology Research Unit

Berlin, 14050, Germany

Location

MeSH Terms

Conditions

Smoking Cessation

Interventions

sembragiline; Nicotine Replacement Therapy

Condition Hierarchy (Ancestors)

Health Behavior; Behavior

Intervention Hierarchy (Ancestors)

Drug Therapy; Therapeutics

Study Officials

• Alla Radicke, MD

  Parexel International GmbH, Clinical Pharmacology Research Unit

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: February 13, 2008
• First Posted: February 25, 2008
• Study Start: February 1, 2008
• Primary Completion: May 1, 2008
• Study Completion: May 1, 2008
• Last Updated: June 17, 2008

Record last verified: 2008-06

Locations

DE (1)